NCT00854685View on ClinicalTrials.gov

Dose Optimisation Study of ART621 in Subjects Diagnosed With Rheumatoid Arthritis Taking Methotrexate

PHASE2CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

February 28, 2009

Primary Completion Date

December 31, 2009

Study Completion Date

January 31, 2010

Conditions
Rheumatoid Arthritis
Interventions
DRUG

ART621

3.0mg/kg s.c. - weekly

DRUG

ART621

3.0mg/kg s.c. - fortnightly

DRUG

ART621

1.5mg/kg s.c. - weekly

DRUG

ART621

1.5mg/kg s.c. - fortnightly

DRUG

Placebo

Placebo s.c. - weekly

DRUG

Placebo

Placebo s.c. - fortnightly

Trial Locations (1)

Unknown

Departement of Rheumatology, National Hospital Sri Lanka, Colombo

Sponsors
All Listed Sponsors
collaborator

Trident Clinical Research Pty Ltd

INDUSTRY

lead

Arana Therapeutics Ltd

INDUSTRY

NCT00854685 - Dose Optimisation Study of ART621 in Subjects Diagnosed With Rheumatoid Arthritis Taking Methotrexate | Biotech Hunter | Biotech Hunter